Expertise in
26
conditions

Dr. Neil Korman

Dermatology
University Hospitals
11100 Euclid Ave, 
Cleveland, OH 
Offers Telehealth
Referral may be required
Expertise in
26
conditions
University Hospitals
11100 Euclid Ave, 
Cleveland, OH 

Overview

Neil Korman is a Dermatologist practicing medicine in Cleveland, Ohio.

Dr. Korman is highly rated in 26 conditions, according to our data. His clinical expertise encompasses Psoriasis, Plaque Psoriasis, Bullous Pemphigoid, and Pemphigus.

He is actively involved in clinical research, co-authoring 75 peer reviewed articles and participating in 18 clinical trials.

Specialties

Dermatology

Licenses

Dermatology in OH

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Buckeye Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
CareFirst
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
First Health
  • INSURANCE PLAN
  • MEDICARE PDP
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medical Health
  • HMO
  • PPO
Medical Mutual
  • HMO
  • PPO
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
Paramount
  • EPO
  • HMO
  • INDEMNITY
  • PPO
Sanford
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
SummaCare
  • HMO
  • PPO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 24 Less Insurance Carriers -

Locations

University Hospitals
11100 Euclid Ave, Cleveland, OH 44106

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

14 Clinical Trials

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Operationally Seamless, Adaptive Phase 2/3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Operationally Seamless, Adaptive Phase 2/3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
Enrollment Status: Completed
Publish Date: April 16, 2026
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 2/Phase 3
A Multicenter, Randomized, Double-Blind, Placebo- Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
A Multicenter, Randomized, Double-Blind, Placebo- Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
Enrollment Status: Completed
Publish Date: April 07, 2026
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
Enrollment Status: Completed
Publish Date: November 05, 2025
Intervention Type: Biological
Study Drug: Lebrikizumab
Study Phase: Phase 3
Phase 2a Prospective, Randomized, Double-blind, Intra-subject, Placebo-controlled, Proof of Concept Study to Evaluate the Efficacy of OLX10010 as an Adjunct Therapy to Reduce the Recurrence of Hypertrophic Scars After Scar Revision Surgery
Phase 2a Prospective, Randomized, Double-blind, Intra-subject, Placebo-controlled, Proof of Concept Study to Evaluate the Efficacy of OLX10010 as an Adjunct Therapy to Reduce the Recurrence of Hypertrophic Scars After Scar Revision Surgery
Enrollment Status: Completed
Publish Date: February 21, 2024
Intervention Type: Drug
Study Phase: Phase 2
A Phase 3, 16-week, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Phase 3, 16-week, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients With Moderate-to-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: October 17, 2023
Intervention Type: Drug
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of LY3041658 in Adults With Moderate-to-Severe Hidradenitis Suppurativa
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of LY3041658 in Adults With Moderate-to-Severe Hidradenitis Suppurativa
Enrollment Status: Completed
Publish Date: April 28, 2023
Intervention Type: Drug
Study Drug: LY3041658
Study Phase: Phase 2
A Multicenter, Long-Term Extension to Evaluate the Long-term Safety and Maintenance of Treatment Effect of LY3074828 in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-3
A Multicenter, Long-Term Extension to Evaluate the Long-term Safety and Maintenance of Treatment Effect of LY3074828 in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-3
Enrollment Status: Terminated
Publish Date: March 21, 2023
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
An Investigator Initiated Study of Monocyte Biomarkers in Moderate to Severe Plaque Psoriasis Subjects Treated With Apremilast
An Investigator Initiated Study of Monocyte Biomarkers in Moderate to Severe Plaque Psoriasis Subjects Treated With Apremilast
Enrollment Status: Completed
Publish Date: January 20, 2023
Intervention Type: Drug
Study Drug: Apremilast
Study Phase: Phase 2
A Multicenter, Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
A Multicenter, Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
Enrollment Status: Terminated
Publish Date: November 08, 2022
Intervention Type: Drug
Study Drug: Baricitnib
Study Phase: Phase 3
A Double Blind Randomized Vehicle Controlled Crossover Study to Evaluate the Safety and Efficacy of Topical Naloxone Hydrochloride Lotion 0.5% for the Relief of Pruritus in Patients With the MF or SS Forms of Cutaneous T-Cell Lymphoma
A Double Blind Randomized Vehicle Controlled Crossover Study to Evaluate the Safety and Efficacy of Topical Naloxone Hydrochloride Lotion 0.5% for the Relief of Pruritus in Patients With the MF or SS Forms of Cutaneous T-Cell Lymphoma
Enrollment Status: Terminated
Publish Date: October 28, 2022
Intervention Type: Drug
Study Drug: Naloxone Hydrochloride Lotion
Study Phase: Phase 3
View 9 Less Clinical Trials

75 Total Publications

Association Between Hurley Stage and Comorbidities in Hidradenitis Suppurativa.
Association Between Hurley Stage and Comorbidities in Hidradenitis Suppurativa.
Journal: International journal of dermatology
Published: September 25, 2025
Similar Doctors
Expertise in
74
conditions
Dr. Wilma Bergfeld
Dermatology
Expertise in
74
conditions
Dr. Wilma Bergfeld
Dermatology
Referral may be required

Cleveland Clinic Main Campus

2049 East 100th Street, 
Cleveland, OH 
 (0.6 miles away)
216-444-2200
Experience:
66+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Wilma Bergfeld is a Dermatologist practicing medicine in Cleveland, Ohio. She has been practicing medicine for over 66 years. Dr. Bergfeld is highly rated in 74 conditions, according to our data. Her clinical expertise encompasses Autosomal Recessive Hypotrichosis, Graham-Little-Piccardi-Lassueur Syndrome, Alopecia Areata, Squamous Cell Skin Carcinoma, and Osteotomy. Dr. Bergfeld is board certified in American Board Of Dermatology, 1974.

Expertise in
93
conditions
Expertise in
93
conditions
Referral may be required

Cleveland Clinic Main Campus

2049 East 100th Street, 
Cleveland, OH 
 (0.6 miles away)
216-444-2200
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Anthony Fernandez is a Dermatologist practicing medicine in Cleveland, Ohio. Dr. Fernandez is highly rated in 93 conditions, according to our data. His clinical expertise encompasses Dermatomyositis, Pyoderma Gangrenosum, Acute Febrile Neutrophilic Dermatosis, and Cutaneous Lupus Erythematosus (CLE). Dr. Fernandez is board certified in American Board Of Dermatology, 2011.

Expertise in
68
conditions
Expertise in
68
conditions
Referral may be required

Cleveland Clinic Main Campus

2049 East 100th Street, 
Cleveland, OH 
 (0.6 miles away)
216-444-2200
Experience:
29+ years
Languages Spoken:
English
See accepted insurances

Melissa Piliang is a Dermatologist practicing medicine in Cleveland, Ohio. She has been practicing medicine for over 29 years. Dr. Piliang is highly rated in 68 conditions, according to our data. Her clinical expertise encompasses Autosomal Recessive Hypotrichosis, Graham-Little-Piccardi-Lassueur Syndrome, Alopecia Areata, and Basal Cell Skin Cancer. Dr. Piliang is board certified in American Board Of Dermatology, 2006.

Frequently Asked Questions about Dr. Neil Korman

How do I make an appointment with Dr. Neil Korman?

You can book an appointment with Dr. Neil Korman by calling their office at 216-844-8200. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Neil Korman a top-rated expert for Psoriasis?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Neil Korman is classified as an Elite expert for Psoriasis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Neil Korman specialize in?

While Dr. Neil Korman is a Dermatology, they have specific expertise in Psoriasis, Plaque Psoriasis, and Bullous Pemphigoid. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Dermatology.

Does Dr. Neil Korman participate in research or clinical trials?

Yes. Dr. Neil Korman has published 75 articles and abstracts on conditions like Psoriasis. You can view a list of Dr. Neil Korman's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Neil Korman accept my insurance?

Dr. Neil Korman accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 216-844-8200 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Korman's expertise for a condition
ConditionClose
View All 8 Distinguished Conditions
View All 16 Advanced Conditions
View All 92 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile